Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Empowered patients improve outcomes

April 27, 2018 | patient activation, patient empowerment, patient engagement 

This white paper co-authored by our own Caroline Benson and Guy Yeoman, MediPaCe, discusses why non-adherence is occurring, how patients’ can be better engaged with their conditions and treatments and provides examples and results of patient engagement in action.


Non-adherence to medication is not a new global healthcare concern but with more people living with long-term conditions the problem is increasing[1]. A difficult problem to solve, this multifaceted phenomenon[2] can have a variety of negative effects for society and for the individuals involved.  

This white paper co-authored by our own Caroline Benson and Guy Yeoman, MediPaCe, discusses why non-adherence is occurring, how patients’ can be better engaged with their conditions and treatments and provides examples and results of patient engagement in action.  

Access the white paper here: 
http://cuttsyandcuttsy.com/blogs/Apr-2018/empowering-patients

1. Clyne W, et al. BMJ Open 2016; 6:e009610.
2. Kvarnström K, et al. BMJ Open 2018;8: e015332. doi:10.1136/bmjopen-2016-015332

This content was provided by Cuttsy + Cuttsy

Company Details

Cuttsy and Cuttsy Logo

Cuttsy + Cuttsy

Email
Website

 Latest Content from  Cuttsy + Cuttsy 

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.

5 key takeaways from the Patient Centricity and Engagement Conference

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.

It’s time to stop calling adverse events ‘manageable’

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.

The value: why localisation pays off across global trials

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.

The solution: Good localisation doesn’t feel translated

Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.

Healthcare information is becoming easier to access. Trust isn’t.

Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.

It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment

ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.